Linked Life Data

3282033

Source:http://linkedlifedata.com/resource/pubmed/id/3282033

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3282033rdf:typepubmed:Citationlld:pubmed
pubmed-article:3282033lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3282033lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:3282033lifeskim:mentionsumls-concept:C1518578lld:lifeskim
pubmed-article:3282033lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:3282033lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:3282033lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:3282033lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:3282033lifeskim:mentionsumls-concept:C1527249lld:lifeskim
pubmed-article:3282033lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:3282033lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:3282033pubmed:issue4lld:pubmed
pubmed-article:3282033pubmed:dateCreated1988-5-18lld:pubmed
pubmed-article:3282033pubmed:abstractTextFrom May 1984 through December 1986, 141 patients with metastatic adenocarcinoma of the colon or rectum were entered on this Hoosier Oncology Group (HOG) trial evaluating the role of cisplatin in systemic therapy. Patients were stratified by the presence or absence of hepatic metastases and by performance status, and were subsequently randomized to receive fluorouracil (5-FU) (15 mg/kg/wk) alone or the same dose of 5-FU plus cisplatin (60 mg/m2 every 3 weeks). The total duration of treatment was six cycles (18 weeks). In 132 fully evaluable patients the objective response rates were 19% for 5-FU and 22% for 5-FU plus cisplatin. Statistically, the median survival times of 40 and 39 weeks were not significantly different (P = .62). However, the median duration of remission (MDR) was superior (P = .05) for 5-FU alone. This study fails to confirm clinically significant synergy of 5-FU plus cisplatin in the treatment of metastatic colorectal cancer.lld:pubmed
pubmed-article:3282033pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3282033pubmed:languageenglld:pubmed
pubmed-article:3282033pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3282033pubmed:citationSubsetIMlld:pubmed
pubmed-article:3282033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3282033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3282033pubmed:statusMEDLINElld:pubmed
pubmed-article:3282033pubmed:monthAprlld:pubmed
pubmed-article:3282033pubmed:issn0732-183Xlld:pubmed
pubmed-article:3282033pubmed:authorpubmed-author:TurneyHHlld:pubmed
pubmed-article:3282033pubmed:authorpubmed-author:MeyerSSlld:pubmed
pubmed-article:3282033pubmed:authorpubmed-author:CorreaJJlld:pubmed
pubmed-article:3282033pubmed:authorpubmed-author:StephensDDlld:pubmed
pubmed-article:3282033pubmed:authorpubmed-author:HuiSSlld:pubmed
pubmed-article:3282033pubmed:authorpubmed-author:WoodburnRRlld:pubmed
pubmed-article:3282033pubmed:authorpubmed-author:AnsariRRlld:pubmed
pubmed-article:3282033pubmed:authorpubmed-author:LoehrerP...lld:pubmed
pubmed-article:3282033pubmed:authorpubmed-author:KubilisPPlld:pubmed
pubmed-article:3282033pubmed:issnTypePrintlld:pubmed
pubmed-article:3282033pubmed:volume6lld:pubmed
pubmed-article:3282033pubmed:ownerNLMlld:pubmed
pubmed-article:3282033pubmed:authorsCompleteYlld:pubmed
pubmed-article:3282033pubmed:pagination642-8lld:pubmed
pubmed-article:3282033pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:meshHeadingpubmed-meshheading:3282033-...lld:pubmed
pubmed-article:3282033pubmed:year1988lld:pubmed
pubmed-article:3282033pubmed:articleTitleA prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial.lld:pubmed
pubmed-article:3282033pubmed:affiliationHoosier Oncology Group, Walther Medical Research Institute, Indianapolis, IN 46208.lld:pubmed
pubmed-article:3282033pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3282033pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3282033pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3282033pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:3282033pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:3282033pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3282033lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3282033lld:pubmed